ES2337037T3 - Ciertos heterociclos aminoalquilicos sustituidos farmaceuticamente utiles. - Google Patents

Ciertos heterociclos aminoalquilicos sustituidos farmaceuticamente utiles. Download PDF

Info

Publication number
ES2337037T3
ES2337037T3 ES03719457T ES03719457T ES2337037T3 ES 2337037 T3 ES2337037 T3 ES 2337037T3 ES 03719457 T ES03719457 T ES 03719457T ES 03719457 T ES03719457 T ES 03719457T ES 2337037 T3 ES2337037 T3 ES 2337037T3
Authority
ES
Spain
Prior art keywords
alkyl
alk
acid
het
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03719457T
Other languages
English (en)
Spanish (es)
Inventor
Scott K. Thompson
James S. Frazee
Lara S. Kallander
Chum Ma
Joseph P. Marino
Michael J. Neeb
Ajita Bhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Application granted granted Critical
Publication of ES2337037T3 publication Critical patent/ES2337037T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES03719457T 2002-03-27 2003-03-26 Ciertos heterociclos aminoalquilicos sustituidos farmaceuticamente utiles. Expired - Lifetime ES2337037T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36841502P 2002-03-27 2002-03-27
US368415P 2002-03-27

Publications (1)

Publication Number Publication Date
ES2337037T3 true ES2337037T3 (es) 2010-04-20

Family

ID=28675483

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03719457T Expired - Lifetime ES2337037T3 (es) 2002-03-27 2003-03-26 Ciertos heterociclos aminoalquilicos sustituidos farmaceuticamente utiles.

Country Status (8)

Country Link
US (1) US7323494B2 (enExample)
EP (1) EP1490047B1 (enExample)
JP (1) JP2005521705A (enExample)
AT (1) ATE453389T1 (enExample)
AU (1) AU2003223340A1 (enExample)
DE (1) DE60330758D1 (enExample)
ES (1) ES2337037T3 (enExample)
WO (1) WO2003082192A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509161A (ja) * 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
AU2003220558A1 (en) 2002-03-27 2004-06-03 Smithkline Beecham Corporation Amide compounds and methods of using the same
JP2005521721A (ja) 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
JP2006512280A (ja) 2002-03-27 2006-04-13 スミスクライン・ビーチャム・コーポレイション 化合物および方法
CA2504878A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
IL166149A0 (en) * 2005-01-05 2006-01-15 Hadasit Med Res Service Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
ATE544756T1 (de) 2006-11-30 2012-02-15 Kowa Co Substituierte carbinolverbindungen
EP2248811B1 (en) 2008-02-29 2012-11-14 Kowa Company, Ltd. 2-oxochromene derivative
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
WO2009133692A1 (ja) 2008-04-30 2009-11-05 興和株式会社 キノリン化合物
EA018584B1 (ru) 2008-05-29 2013-09-30 Кова Компани, Лтд. Замещённое карбинольное соединение, содержащее циклический линкер
MX2011011281A (es) 2009-04-29 2012-02-22 Kowa Co Compuesto de carbinol que tiene un enlazante heterociclico.
RU2013115395A (ru) 2010-09-07 2014-10-20 СНУ Ар энд ДиБи ФАУНДЕЙШН Сестертерпеновое соединение и его применение
KR20240032149A (ko) 2017-03-03 2024-03-08 인스피르나, 인크. 향상된 안정성을 갖는 제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394440B1 (en) 1987-10-20 1994-05-11 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
WO2001060818A1 (en) 2000-02-14 2001-08-23 Tularik Inc. Lxr modulators
JP2004509161A (ja) * 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
CA2468989A1 (en) * 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
AU2003220558A1 (en) 2002-03-27 2004-06-03 Smithkline Beecham Corporation Amide compounds and methods of using the same
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
JP2005521721A (ja) 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
JP2006512280A (ja) * 2002-03-27 2006-04-13 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20050036992A1 (en) * 2002-12-23 2005-02-17 Irm Llc Novel use of liver X receptor agonists
GB0230177D0 (en) 2002-12-24 2003-02-05 Karobio Ab LXR beta crystal
EP1635773A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
JP2006528200A (ja) 2003-07-22 2006-12-14 グラクソ　グループ　リミテッド Ｌｘｒアゴニストを用いる治療方法
JP2007500158A (ja) 2003-07-28 2007-01-11 グラクソ　グループ　リミテッド Ｌｘｒアゴニストを用いる炎症性腸疾患の治療方法
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
AU2004298486A1 (en) * 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
MXPA06014576A (es) 2004-06-24 2007-03-23 Galapagos Nv Agonistas de lxr para promover homeostasis osea.
CA2572872C (en) 2004-07-02 2013-10-22 Sankyo Company Limited Tissue factor production inhibitor

Also Published As

Publication number Publication date
US20050165045A1 (en) 2005-07-28
ATE453389T1 (de) 2010-01-15
WO2003082192A3 (en) 2003-12-18
EP1490047B1 (en) 2009-12-30
EP1490047A4 (en) 2006-01-04
JP2005521705A (ja) 2005-07-21
AU2003223340A1 (en) 2003-10-13
AU2003223340A8 (en) 2003-10-13
EP1490047A2 (en) 2004-12-29
WO2003082192A2 (en) 2003-10-09
US7323494B2 (en) 2008-01-29
DE60330758D1 (de) 2010-02-11

Similar Documents

Publication Publication Date Title
ES2337037T3 (es) Ciertos heterociclos aminoalquilicos sustituidos farmaceuticamente utiles.
ES2233700T3 (es) Derivados de aminopropoxiarilo sustituidos utiles como agonistas para lxr.
ES2349164T3 (es) Derivados de 3-(sulfonamidoetil)-indol para uso como compuestos miméticos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alérgicas y proliferativas.
ES2247298T3 (es) Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
ES2276038T3 (es) Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
ES2542021T3 (es) Derivados amida del ácido piperidina- y piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (faah) para el tratamiento de la ansiedad, el dolor y otras afecciones
ES2274201T3 (es) Agonistas del receptor de melanocortina.
ES2326907T3 (es) Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y su uso.
US20040224992A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20100063282A1 (en) Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions, and Uses Thereof
US20040116455A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EA002778B1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
US20100048950A1 (en) Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
ES2321055T3 (es) Compuestos biblicos sustituidos.
KR20080072688A (ko) 옥사디아졸 유도체
Czopek et al. Synthesis and pharmacological evaluation of new 5-(cyclo) alkyl-5-phenyl-and 5-spiroimidazolidine-2, 4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity
WO2009123080A1 (ja) インドリノン化合物
KR100860692B1 (ko) 축합 환식기를 가지는 환상 디아민 화합물
KR20050106421A (ko) 카르복실산 화합물
CN110776486B (zh) 一种苯并呋喃类小分子p2y14受体抑制剂，及其制备和应用
ES2621901T3 (es) Derivados de piperazinil pirimidinas, método de preparación y su uso
WO2005023188A2 (en) Compounds and methods
WO2005023247A1 (en) Compounds and methods
CN108586425B (zh) 一种烷氧基联苯α,β-不饱和酰胺类化合物、其制备方法及医药用途
JP2009507815A (ja) チアゾール化合物およびｐｇｄ２アンタゴニストとしてのその使用